While immune checkpoint inhibitors (ICIs) can provide lifesaving treatment for patients with cancer, they have also been found to cause immune-related adverse events (irAEs)—side effects that can impact almost every organ in the body to varying degrees. The frequency and severity of irAEs in real-world datasets are not well understood, making it difficult to combine cases effectively across institutions and gain insights into the optimal management of these patients.
This article was originally published on MedicalXpress.com
